Clinical trials: Infections, Respiratory
COVID-19
A Phase II/III Study of Sargramostim
This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days, in principle (up to 10 days) as Add-on…
- Trial name
- NCT04642950
- Testing
- Sargramostim
- Where
- 7 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Nobelpharma
COVID-19
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a…
- Trial name
- VAT00008 (NCT04904549)
- Testing
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
- Where
- 86 sites in United States, Colombia and 9 more
- Volunteers
- 23,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19 Immunization, Influenza Immunization
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
- Trial name
- NCT06695117
- Testing
- IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1)
- Where
- 12 sites in United States
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Sanofi
Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
This study investigated the efficacy of inhaled TOBI treatment for early infections of P. aeruginosa in paediatric patients with cystic fibrosis.
- Trial name
- EARLY (NCT01082367)
- Testing
- TOBI
- Where
- 19 sites in Canada, Egypt and 8 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Influenza
Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK
This study aims to assess the risk of solid organ transplant (SOT) rejection following vaccination with Pandemrix™ and/ or seasonal influenza vaccination.
- Trial name
- NCT01715792
- Testing
- Data collection
- Where
- United Kingdom
- Volunteers
- 587 people
- Sponsor
- GlaxoSmithKline
SARS-CoV-2 Infection, Anti-SARS-CoV-2 Infection
Registry of Sustained Immunity to COVID-19 Among ESKD Patients
This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center.
- Trial name
- RePAiR (NCT04495764)
- Where
- 12 sites in United States
- Volunteers
- 2,315 people
- Sponsor
- Davita Clinical Research
Covid19
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.
An Adaptive, Randomized, Double-blind, Placebo-controlled study to examine the Effects of Tempol in subjects with COVID-19 infection.
- Trial name
- NCT04729595
- Testing
- Tempol
- Where
- 17 sites in United States
- Volunteers
- 248 people
- Sponsor
- Adamis Pharmaceuticals Corporation
Orthomyxoviridae Infection, Influenza
Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults
The primary objective of this trial is to demonstrate the equivalence, in terms of immunogenicity, of three different industrial lots of the investigational vaccine thereby supporting consistency of the manufacturing process.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00383539
- Testing
- Inactivated Split-virion influenza vaccine
- Where
- 4 sites in France, Lithuania and 2 more
- Volunteers
- 2,256 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rhinitis, Allergic, Seasonal
A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
This study compared the safety and efficacy of a generic fluticasone furoate (Lek Pharmaceuticals) nasal spray to the reference listed drug in the treatment of seasonal allergic rhinitis.
- Trial name
- NCT01279057
- Testing
- Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray
- Where
- 7 sites in United States
- Volunteers
- 727 people
- Sponsor
- Sandoz
Influenza
Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects
This study will evaluate safety and immunogenicity of surface, antigen, inactivated, influenza vaccine produced in mammalian cell culture when administered to adult and elderly subject.
- Trial name
- NCT01422512
- Testing
- seasonal influenza vaccine
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
COVID 19
Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 in Healthy Adult Subjects
- Trial name
- NCT04583228
- Testing
- HLX71
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hengenix Biotech Inc
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
Chronic Rhinosinusitis (CRS), Exacerbations
Effect of Pleuran on the Clinical Course of Patients With Chronic Rhinosinusitis
The goal of this clinical research is to learn if Imunoglukan P4H® as an add-on therapy to the standard of care treatment according to the EPOS guidelines (intranasal corticosteroids and saline irrigation) can help to prevent CRS…
- Conditions
- Chronic Rhinosinusitis (CRS), Exacerbations, Respiratory Tract Infections (RTI), Antibiotic Prophylaxis
- Trial name
- EPCCOR (NCT07460934)
- Testing
- Imunoglukan P4H® capsules
- Where
- 5 sites in Czechia, Slovakia
- Volunteers
- 85 people
- Sponsor
- Pleuran, s.r.o.
Bacterial Pneumonia
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
This study aims to compare treatment with a fixed-dose combination (FDC) of imipenem/relebactam/cilastatin (IMI/REL) with a FDC of piperacillin/tazobactam (PIP/TAZ) in participants with hospital-acquired or ventilator-associated…
- Trial name
- RESTORE-IMI 2 (NCT02493764)
- Testing
- Imipenem, Relebactam, Cilastatin
- Volunteers
- 537 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19, Immune Response
Immunomodulatory Effect of Probiotics on the Immunogenicity of Anti-SARS-CoV-2 Vaccines
This study aims to evaluate whether oral probiotic supplementation can modulate the immune response induced by COVID-19 vaccination.
- Trial name
- NCT07610512
- Testing
- Probiotics
- Where
- Taiwan
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Grape King Bio Ltd.
Bronchitis, Chronic
AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs
The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin…
- Trial name
- NCT00846911
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 8 sites in Albania, Bosnia and Herzegovina and 6 more
- Volunteers
- 2,672 people
- Sponsor
- Bayer
COVID-19
Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19
Safety and Effectiveness Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the treatment of patients with COVID-19
- Trial name
- CP022 (NCT04547257)
- Testing
- Seraph 100
- Where
- 5 sites in Germany, Spain
- Volunteers
- 42 people
- Sponsor
- ExThera Medical Corporation
Influenza
A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.
This observer-blind study is designed to show the immunological non-inferiority of Thiomersal-free-processed pandemic influenza vaccine as compared to the Thiomersal-containing-processed pandemic influenza vaccine.
- Trial name
- NCT00812981
- Testing
- GSK1562902A
- Where
- Taiwan
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Tract Infections
Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of PF-04287881 after a single oral dose in healthy adult volunteers.
- Trial name
- NCT00793000
- Testing
- PF-04287881
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.